1. Home
  2. DERM vs UNCY Comparison

DERM vs UNCY Comparison

Compare DERM & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DERM

Journey Medical Corporation

HOLD

Current Price

$6.00

Market Cap

135.3M

Sector

Health Care

ML Signal

HOLD

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$6.66

Market Cap

145.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DERM
UNCY
Founded
2014
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.3M
145.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DERM
UNCY
Price
$6.00
$6.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$12.67
$25.67
AVG Volume (30 Days)
266.2K
699.6K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
34.72
N/A
EPS
N/A
N/A
Revenue
$61,858,000.00
$675,000.00
Revenue This Year
$39.72
N/A
Revenue Next Year
$63.24
$582.86
P/E Ratio
N/A
N/A
Revenue Growth
10.20
N/A
52 Week Low
$4.31
$0.47
52 Week High
$9.56
$8.74

Technical Indicators

Market Signals
Indicator
DERM
UNCY
Relative Strength Index (RSI) 52.77 38.94
Support Level $5.77 $6.17
Resistance Level $6.59 $7.22
Average True Range (ATR) 0.31 0.54
MACD -0.02 -0.12
Stochastic Oscillator 33.33 1.16

Price Performance

Historical Comparison
DERM
UNCY

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Share on Social Networks: